Smoother lipid delivery
Croda Chemicals Europe used the CPhI exhibition in Frankfurt this
week as a platform to launch two new excipients for drug delivery.
The healthcare division of UK-based speciality chemicals maker Croda Chemicals Europe used the CPhi exhibition in Frankfurt this week as a platform to launch two new excipients for drug delivery.
Manufactured to GMP standards, the surface active glyceryl esters for oral and topical applications Crossential GMO and Crossential GDO, "offer the potential for enhanced active bioavailability coupled with controlled drug release," said the company in a statement.
Crossential GMO is a high purity grade of glyceryl monooleate, containing a minimum of 90 per cent monoester and 84 per cent oleic acid.
"With its liquid crystalline structure in aqueous systems and ability to enhance membrane penetration, Crossential GMO offers sustained drug release and greater bioavailability for pharmaceutical applications, particularly oral dosage forms", said Croda this week.
The second excipient, Crossential GDO, is a high purity glyceryl dioleate - minimum 90 per cent diester and 84 per cent oleic acid - is a more lipophilic variant.
By combining different ratios of Crossential GMO and GDO formulators can optimise delivery systems according to particular actives and applications, claimed the UK company.
